Steven Grant, MD [clinicaltrials_resource:f5766fa13881fdf8fc2f89f6ed80e13d]
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies [clinicaltrials:NCT00002818]Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma [clinicaltrials:NCT00003079]Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma [clinicaltrials:NCT00005580]Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia [clinicaltrials:NCT00017342]Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00064285]
overall official [clinicaltrials_vocabulary:overall-official]
Steven Grant, MD [clinicaltrials_resource:f5766fa13881fdf8fc2f89f6ed80e13d]
Bio2RDF identifier
f5766fa13881fdf8fc2f89f6ed80e13d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f5766fa13881fdf8fc2f89f6ed80e13d
affiliation [clinicaltrials_vocabulary:affiliation]
last name [clinicaltrials_vocabulary:last-name]
Steven Grant, MD
role [clinicaltrials_vocabulary:role]
Study Chair
identifier
clinicaltrials_resource:f5766fa13881fdf8fc2f89f6ed80e13d
title
Steven Grant, MD
@en
type
label
Steven Grant, MD [clinicaltrials_resource:f5766fa13881fdf8fc2f89f6ed80e13d]
@en